The Cancer Biopsy Market revenues were estimated at US$ 22.2 Bn in 2022 and are anticipated to grow at a CAGR of 18% from 2023-2033, according to a recently published Future Market Insights report. By the end of 2033, the market is expected to reach US$ 131.4 Bn.
The increasing elderly populace, along with the rise in instances of cancer diagnoses, is fueling growth in the cancer clinical market. Also, the effective and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.
Get Your Hands on the Complimentary Visuals Report Today! Get Latest Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16508
Some of today’s prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which have been found to be less invasive and faster, are aiding the increase in popularity of the slice.
The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.
Master the Insights: Connect with Experts Today! Speak to Our Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16508
Competitive Analysis
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
Key recent developments of key players in the Cancer Biopsy Market are as follows:
- In March 2021, in Russia, KIllumina, Inc. received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with Quick-Core IZI Medical Products introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company’s patented semi-automatic method.
Competitive Landscape
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
- In March 2021, In Russia, KIllumina, Inc. has received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with a Quick-Core IZI Medical Products has introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company’s patented semi-automatic method.
- In April 2021, Plasma-SeqSensei liquid biopsy research use only (RUO) kits were introduced in EMEA by Sysmex Europe GmbH and Sysmex Inostics GmbH.
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Cancer Biopsy Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of by Type (Tissue Biopsies, Liquid biopsies, Other Types), by Product Type (Instruments, Kits and Consumables, Services), by Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Other Applications) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Secure your sample report enriched with captivating data visualizations. Request Report Methodology @ https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16508
Market Segments Covered in Cancer Biopsy Industry Analysis
By Type:
- Tissue Biopsies
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Other Types
By Product Type:
- Instruments
- Kits and Consumables
- Services
By Application:
- Breast Cancer
- Colorectal Cancer
- Cervical Cancers
- Lung Cancers
- Prostate Cancers
- Skin Cancers
- Blood Cancers
- Kidney Cancers
- Liver Cancers
- Pancreatic Cancers
- Ovarian Cancers
- Other Applications
Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:
Patient Portal Market: The global patient portal market is estimated at US$ 3 Billion in 2021 and is expected to secure US$ 3.6 Billion by 2022. The market is projected to procure US$ 22.29 Billion by 2032 while expanding at a staggering double-digit CAGR of 20% during the forecast period from 2022 to 2032.
Bariatric Surgery Devices Market: The bariatric surgery devices market is growing at a moderate pace with a CAGR of 6.2% during the forecast period 2022 to 2032.
Mammography Market: The anticipated size of the mammography market in 2022 was US$ 1,741.2 million and is estimated to be US$ 1,880.2 million in 2023.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube